OXFORD, UK – 8th May 2013 – PsiOxus Therapeutics, Ltd. (PsiOxus), a development stage biotechnology company, today announced that Dr. Christine Wilkinson Blanc has joined the company’s management team as Chief Medical Officer. In her new role, Dr. Wilkinson Blanc will focus her efforts on overseeing and advancing PsiOxus Therapeutics’ clinical programs for oncolytic vaccine ColoAd1, and for MT102, a small molecule therapeutic in development for the treatment of cancer cachexia.
Dr. Wilkinson Blanc brings more than 20 years of oncology clinical research and medical affairs experience in the pharmaceutical industry collaborating on prominent clinical development programs, including: docetaxel and irinotecan at Aventis/Rhone-Poulenc Rorer; bevacizumab at Roche; and ridaforolimus at Ariad Pharmaceuticals.
See the full article and other news here
For information on PsiOxus, see the news story University of Birmingham vaccine technology is rising star in new biotech company |
Posted on Friday 17th May 2013